Adoptively Transferred in vitro-Generated Myeloid-Derived Suppressor Cells Improve T-Cell Function and Antigen-Specific Immunity after Traumatic Lung Injury.
Cellular immunity
Immunotherapy
Myeloid-derived suppressor cells
Post-traumatic immunosuppression
Secondary infection
Trauma
Journal
Journal of innate immunity
ISSN: 1662-8128
Titre abrégé: J Innate Immun
Pays: Switzerland
ID NLM: 101469471
Informations de publication
Date de publication:
10 Jun 2022
10 Jun 2022
Historique:
received:
20
12
2021
accepted:
07
05
2022
entrez:
12
6
2022
pubmed:
13
6
2022
medline:
13
6
2022
Statut:
aheadofprint
Résumé
Immune reactions after trauma are characterized by immediate activation of innate immunity and simultaneously downregulation of adaptive immunity leading to a misbalanced immunohomeostasis and immunosuppression of the injured host. Therefore, the susceptibility to secondary infections is strongly increased after trauma. Immune responses are regulated by a network of immune cells influencing each other and at the same time modifying their functions dependent on the inflammatory environment. Although myeloid-derived suppressor cells (MDSCs) are initially described as T-cell suppressors, their immunomodulatory capacity after trauma is mostly undefined. Therefore, in vitro-generated MDSCs were adoptively transferred into mice after blunt chest trauma (TxT). A single MDSC treatment-induced splenic T-cell expansion decreased apoptosis sensitivity and improved proliferation in the absence of T-cell exhaustion until 2 weeks after trauma. MDSC treatment had a long-lasting effect on the genomic landscape of CD4+ T cells by upregulating primarily Th2-associated genes. Remarkably, immune-activating functions of MDSCs supported the ability of TxT mice to respond to post-traumatic secondary antigen challenge. Secondary insults were mimicked by immunizing MDSC-treated TxT mice with ovalbumin (OVA), followed by OVA restimulation in vitro. MDSC treatment significantly increased the frequency of OVA-specific T cells, enhanced their Th1/Th2 cytokine expression, and induced upregulation of cytolytic molecules finally improving OVA-specific cytotoxicity. Overall, we could show that therapeutic MDSC treatment after TxT improves post-traumatic T-cell functions, which might enable the traumatic host to counterbalance trauma-induced immunoparalysis.
Identifiants
pubmed: 35691281
pii: 000525088
doi: 10.1159/000525088
pmc: PMC10643914
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
1-18Informations de copyright
© 2022 The Author(s). Published by S. Karger AG, Basel.
Références
J Immunol. 2006 Feb 15;176(4):2085-94
pubmed: 16455964
Nat Rev Immunol. 2017 Jul;17(7):407-420
pubmed: 28436424
Neuroscience. 2019 May 15;406:457-466
pubmed: 30880103
Sci Rep. 2019 May 29;9(1):7992
pubmed: 31142770
Bioinformatics. 2002 Jan;18(1):207-8
pubmed: 11836235
Genome Biol. 2003;4(4):R28
pubmed: 12702209
Blood. 2000 Dec 1;96(12):3838-46
pubmed: 11090068
Sci Rep. 2017 Oct 9;7(1):12808
pubmed: 28993671
Stem Cell Res Ther. 2018 Jul 4;9(1):183
pubmed: 29973247
J Exp Med. 1998 Jan 5;187(1):129-34
pubmed: 9419219
Crit Care. 2014 Aug 01;18(4):R163
pubmed: 25084831
Blood. 2010 Dec 16;116(25):5738-47
pubmed: 20807889
J Immunol. 2003 Aug 1;171(3):1172-82
pubmed: 12874203
Oncotarget. 2016 Apr 5;7(14):17565-78
pubmed: 27007050
J Exp Med. 2007 Jun 11;204(6):1463-74
pubmed: 17548519
Nat Rev Immunol. 2013 Dec;13(12):862-74
pubmed: 24232462
Adv Cancer Res. 2015;128:95-139
pubmed: 26216631
J Trauma Acute Care Surg. 2012 Sep;73(3):699-703
pubmed: 22710768
Crit Care Med. 2005 Jun;33(6):1351-8
pubmed: 15942355
Ann Rheum Dis. 2019 Jul;78(7):957-966
pubmed: 31040119
Biostatistics. 2003 Apr;4(2):249-64
pubmed: 12925520
Fac Rev. 2021 Mar 15;10:30
pubmed: 33817699
Bone. 2016 Dec;93:113-124
pubmed: 27664567
Mediators Inflamm. 2015;2015:458626
pubmed: 25709155
Cancer Immunol Immunother. 2012 Aug;61(8):1319-25
pubmed: 22546994
Autoimmunity. 2017 May;50(3):170-181
pubmed: 28276713
J Leukoc Biol. 2014 Nov;96(5):685-93
pubmed: 24929004
Shock. 2004 Jul;22(1):51-6
pubmed: 15201702
J Clin Immunol. 2013 May;33(4):798-808
pubmed: 23354838
Int J Cancer. 2019 Mar 1;144(5):933-946
pubmed: 29992569
Chin J Traumatol. 2020 Jun;23(3):125-138
pubmed: 32417043
Shock. 2015 Feb;43(2):140-7
pubmed: 25526372
Blood. 2013 Mar 7;121(10):1740-8
pubmed: 23305737
J Biol Chem. 2019 Apr 19;294(16):6283-6293
pubmed: 30787105
J Leukoc Biol. 2021 Dec;110(6):1143-1161
pubmed: 34636072
Blood. 2015 Aug 27;126(9):1138-48
pubmed: 26185131
Hum Immunol. 2016 Aug;77(8):631-636
pubmed: 27240453
Infect Immun. 2012 Jun;80(6):2026-34
pubmed: 22451518
FASEB J. 2019 May;33(5):5967-5978
pubmed: 30730772
J Immunol. 2010 Jun 1;184(11):6151-60
pubmed: 20427766
Front Immunol. 2018 Jun 11;9:1310
pubmed: 29942309
J Trauma. 1996 Jun;40(6):907-12; discussion 912-4
pubmed: 8656476
J Neuroimmunol. 2016 Jan 15;290:96-102
pubmed: 26711577
Shock. 2020 Jan;53(1):35-42
pubmed: 30998650
Br J Cancer. 2019 Jan;120(1):16-25
pubmed: 30413826
Lancet. 2014 Oct 18;384(9952):1455-65
pubmed: 25390327
J Neurochem. 2013 Apr;125(1):74-88
pubmed: 23278273
Front Microbiol. 2016 Oct 13;7:1624
pubmed: 27790210
Mol Med. 2011 Mar-Apr;17(3-4):281-92
pubmed: 21085745
J Clin Invest. 2021 Mar 15;131(6):
pubmed: 33492309
Front Immunol. 2021 Jul 14;12:695972
pubmed: 34341659
J Exp Med. 2010 Jul 5;207(7):1453-64
pubmed: 20530204
JAMA. 2011 Dec 21;306(23):2594-605
pubmed: 22187279
Int Immunopharmacol. 2020 Jun;83:106421
pubmed: 32217462
Am J Respir Crit Care Med. 2017 Aug 1;196(3):315-327
pubmed: 28146645
Nat Commun. 2016 Jul 06;7:12150
pubmed: 27381735
Nat Immunol. 2018 Apr;19(4):327-341
pubmed: 29507356
J Immunol. 2018 Mar 1;200(5):1543-1553
pubmed: 29463691
Circulation. 2018 Jul 10;138(2):181-197
pubmed: 29437117
Heart. 2018 May;104(9):719-724
pubmed: 29203574
JAMA. 2011 Mar 9;305(10):1001-7
pubmed: 21386078
PLoS One. 2016 Oct 25;11(10):e0164514
pubmed: 27780254